A phase 1 study of SGN-CD228A in select advanced solid tumors
This trial will study the study drug, SGN-CD228A, to find out whether it is an effective way to treat different kinds of cancer. The study will also look at what side effects (unwanted effects) may occur.
Non-small Cell Lung Cancer
Pancreatic Ductal Adenocarcinoma
1. Individuals 18 years or older
2. Adequate organ function
3. Other criteria apply
18 - 100
Healthy Volunteers Needed
Duration of Participation
The length of your participation in this study will depend on how long you receive the study drug. This could range from 1 day to more than 24 months. In this study we may continue to follow you indefinitely through telephone calls, medical record review, and/or clinic visits after you have received the last dose of the study drug(s).
Knight Clinical Trials Information Line